Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001610520-24-000138
Filing Date
2024-08-08
Accepted
2024-08-08 11:36:38
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 3755
  Complete submission text file 0001610520-24-000138.txt   5499
Mailing Address BAHNHOFSTRASSE 45 ZURICH V8 CH-8001
Business Address BAHNHOFSTRASSE 45 ZURICH V8 CH-8001 41-44-234-1111
UBS Group AG (Filed by) CIK: 0001610520 (see all company filings)

EIN.: 000000000 | State of Incorp.: V8 | Fiscal Year End: 1231
Type: SCHEDULE 13G/A
SIC: 6021 National Commercial Banks
(CF Office: 02 Finance)

Mailing Address 83 CLEMENCEAU AVENUE #12-03 UE SQUARE SINGAPORE U0 239920
Business Address 83 CLEMENCEAU AVENUE #12-03 UE SQUARE SINGAPORE U0 239920 65 6222 4235
ASLAN Pharmaceuticals Ltd (Subject) CIK: 0001722926 (see all company filings)

EIN.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-91181 | Film No.: 241186921
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)